{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:29:25Z","timestamp":1793604565519,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY389"],"award-info":[{"award-number":["2023KY389"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.exphem.2025.104862","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T23:12:10Z","timestamp":1754521930000},"page":"104862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming"],"prefix":"10.1016","volume":"151","author":[{"given":"Jiaheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.104862_bib0001","doi-asserted-by":"crossref","first-page":"n2026","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.exphem.2025.104862_bib0002","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"R I Med J (2013)"},{"key":"10.1016\/j.exphem.2025.104862_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","article-title":"Precision therapy for acute myeloid leukemia","volume":"11","author":"Yang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2025.104862_bib0004","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2025.104862_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104862_bib0006","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2013.085209","article-title":"Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials","volume":"99","author":"Pollyea","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2025.104862_bib0007","first-page":"e787","article-title":"RNA modification in normal hematopoiesis and hematologic malignancies","volume":"5","author":"Chen","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.exphem.2025.104862_bib0008","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/cmdc.202000011","article-title":"Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer","volume":"15","author":"Bedi","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.exphem.2025.104862_bib0009","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","article-title":"Targeting FTO suppresses cancer stem cell maintenance and immune evasion","volume":"38","author":"Su","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.104862_bib0010","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1038\/s41388-020-1303-7","article-title":"YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2025.104862_bib0011","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/s41418-023-01234-w","article-title":"YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer","volume":"30","author":"Yuan","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2025.104862_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.stem.2022.12.003","article-title":"Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance","volume":"30","author":"Cheng","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.104862_bib0013","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2018.02.015","article-title":"Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal","volume":"69","author":"Wen","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.104862_bib0014","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jfma.2022.12.019","article-title":"Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation","volume":"122","author":"Xie","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.exphem.2025.104862_bib0015","article-title":"N6-methyladenosine writer gene ZC3H13 predicts immune phenotype and therapeutic opportunities in kidney renal clear cell carcinoma","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2025.104862_bib0016","first-page":"19","article-title":"N(6)-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance","volume":"9","author":"Lin","year":"2022","journal-title":"Mil Med Res"},{"key":"10.1016\/j.exphem.2025.104862_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2023.102187","article-title":"ZC3H13 reduced DUOX1-mediated ferroptosis in laryngeal squamous cell carcinoma cells through m6A-dependent modification","volume":"84","author":"Huang","year":"2023","journal-title":"Tissue Cell"},{"key":"10.1016\/j.exphem.2025.104862_bib0018","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2022.2160134","article-title":"m(6)A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia","volume":"18","author":"Liao","year":"2023","journal-title":"Epigenetics"},{"key":"10.1016\/j.exphem.2025.104862_bib0019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12931-022-02213-4","article-title":"The FoxP1 gene regulates lung function, production of matrix metalloproteinases and inflammatory mediators, and viability of lung epithelia","volume":"23","author":"Andreas","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.exphem.2025.104862_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108818","article-title":"FOXP1 inhibits high glucose-induced ECM accumulation and oxidative stress in mesangial cells","volume":"313","author":"Xiang","year":"2019","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.exphem.2025.104862_bib0021","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/s44319-024-00131-8","article-title":"Foxp1 suppresses cortical angiogenesis and attenuates HIF-1alpha signaling to promote neural progenitor cell maintenance","volume":"25","author":"Buth","year":"2024","journal-title":"EMBO Rep"},{"key":"10.1016\/j.exphem.2025.104862_bib0022","article-title":"FOXP1 inhibits pancreatic cancer growth by transcriptionally regulating IRF1 expression","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2025.104862_bib0023","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1039\/D3SC06558H","article-title":"Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia","volume":"15","author":"Shi","year":"2024","journal-title":"Chem Sci"},{"key":"10.1016\/j.exphem.2025.104862_bib0024","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/16078454.2019.1666219","article-title":"Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia","volume":"24","author":"Hu","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.exphem.2025.104862_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104795","article-title":"The transcription factor Foxp1 regulates aerobic glycolysis in adipocytes and myocytes","volume":"299","author":"Ma","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2025.104862_bib0026","article-title":"NAT10\/ac4C\/FOXP1 promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.exphem.2025.104862_bib0027","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/bloodadvances.2022008585","article-title":"FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells","volume":"7","author":"Levavasseur","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104862_bib0028","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2016-10-747436","article-title":"PUMILIO\/FOXP1 signaling drives expansion of hematopoietic stem\/progenitor and leukemia cells","volume":"129","author":"Naudin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104862_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.exphem.2025.104862_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.blre.2012.11.001","article-title":"Mutational landscape of AML with normal cytogenetics: biological and clinical implications","volume":"27","author":"Martelli","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2025.104862_bib0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2025.104862_bib0032","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/genes11080845","article-title":"AML with myelodysplasia-related changes: development, challenges, and treatment advances","volume":"11","author":"Koenig","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.exphem.2025.104862_bib0033","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/17512433.2020.1850255","article-title":"Novel therapies for AML: a round-up for clinicians","volume":"13","author":"Swaminathan","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.exphem.2025.104862_bib0034","article-title":"Targeted therapy in NPM1-mutated AML: knowns and unknowns","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2025.104862_bib0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK cell therapy in AML","volume":"11","author":"Shao","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.exphem.2025.104862_bib0036","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/cells8080805","article-title":"Metabolic plasticity of acute myeloid leukemia","volume":"8","author":"Kreitz","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.exphem.2025.104862_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108244","article-title":"HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt\/\u03b2-catenin\/PFKP pathway in acute myeloid leukemia cells","volume":"680","author":"Chen","year":"2020","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.exphem.2025.104862_bib0038","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3892\/ol.2016.4600","article-title":"Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia","volume":"12","author":"Song","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.exphem.2025.104862_bib0039","doi-asserted-by":"crossref","first-page":"882","DOI":"10.7150\/ijbs.30290","article-title":"Glycolytic enzyme PKM2 mediates autophagic activation to promote cell survival in NPM1-mutated leukemia","volume":"15","author":"Wang","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.exphem.2025.104862_bib0040","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104862_bib0041","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia","author":"Wouters","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104862_bib0042","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","article-title":"m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer","volume":"37","author":"Huang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.104862_bib0043","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.4416","article-title":"The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells","volume":"23","author":"Vu","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.104862_bib0044","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/0008-5472.CAN-21-4249","article-title":"The RNA m6A reader YTHDF1 is required for acute myeloid leukemia progression","volume":"83","author":"Hong","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2025.104862_bib0045","first-page":"37","article-title":"MALAT-1 regulates the AML progression by promoting the m6A modification of ZEB1","volume":"70","author":"Jin","year":"2023","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.exphem.2025.104862_bib0046","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.104862_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111304","article-title":"METTL14-mediated N6-methyladenosine modification of TCP1 mRNA promotes acute myeloid leukemia progression","volume":"122","author":"Zhang","year":"2024","journal-title":"Cell Signal"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25001535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25001535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:02:36Z","timestamp":1772830956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25001535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0301472X25001535"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104862","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104862"}}